Mirtazapine for Anxiety: How It Works and Who It Helps

Most anxiety medications work by raising serotonin levels. Mirtazapine takes a different path to the same place, and that path matters for who it actually helps.

The standard SSRI increases serotonin by blocking its reuptake. In doing so, it also activates a range of serotonin receptor subtypes, including the ones responsible for nausea, insomnia, and sexual dysfunction. For many patients, this is a manageable tradeoff. For others, the side effects end the treatment before it has a chance to work.

Mirtazapine does not inhibit reuptake of anything. Its mechanism is fundamentally different, and so is the side effect profile, and so is the patient it tends to work best for.

What This Page Covers

• What mirtazapine is and how it works
• Why the mechanism produces fewer of the side effects people quit SSRIs over
• The clinical evidence for anxiety disorders
• Who tends to benefit most
• What to expect from dosing and treatment course
• How SiggyMD approaches mirtazapine prescribing

What Mirtazapine Is

Mirtazapine (brand name Remeron) is an atypical tetracyclic antidepressant, and the only noradrenergic and specific serotonergic antidepressant (NaSSA) available in the United States. It is FDA-approved for the management of major depressive disorder in adults. Off-label clinical use includes anxiety disorders, PTSD, insomnia, panic disorder, and OCD.

The drug has been available in the United States since 1996 and in generic form since 2004. It is taken once daily, typically at bedtime, in doses ranging from 15 to 45 mg per day.

The Mechanism: Why Mirtazapine Is Not an SSRI

Understanding why mirtazapine is different requires understanding how it works at the receptor level.

Mirtazapine inhibits central presynaptic alpha-2 adrenergic receptors, leading to increased serotonin and norepinephrine release. It also acts as a potent antagonist of histamine H1 receptors and serotonin 5-HT2A, 5-HT2C, and 5-HT3 receptors.

Breaking that down plainly:

The alpha-2 blockade is the primary mechanism. Alpha-2 receptors normally act as a brake on the release of norepinephrine and serotonin. When mirtazapine blocks them, both neurotransmitters are released more freely. This is how mirtazapine achieves its antidepressant and anxiolytic effects, not through reuptake inhibition, but through disinhibiting release.

SSRIs typically activate postsynaptic 5-HT2A and 5-HT3 receptors, which can cause anxiety, insomnia, nausea, and sexual dysfunction. Mirtazapine is an antagonist of these same receptors, which reduces anxiety and depressive symptoms while lacking the side effects typically found with 5-HT activation. This explains mirtazapine’s more benign side effect profile compared to SSRIs.

The H1 blockade is responsible for mirtazapine’s sedation and appetite-stimulating effects. It is one of the most potent H1 inverse agonists among antidepressants.

This produces a counterintuitive dose-sedation relationship: lower doses of mirtazapine are often more sedating than higher doses because at lower doses the H1 antihistamine activity dominates, while at higher doses the noradrenergic stimulating effects partially counteract the sedation.

What the Evidence Shows for Anxiety

Mirtazapine is not FDA-approved for anxiety disorders. Its use for anxiety is off-label, based on clinical studies and prescriber judgment.

A 2026 systematic review and meta-analysis of 37 studies found that in generalized anxiety disorder, mirtazapine paralleled SSRIs in efficacy. This is a meaningful finding: equivalence to the established first-line treatment suggests mirtazapine is a clinically viable option, particularly when SSRIs are not well-tolerated.

There are studies supporting mirtazapine’s use in anxiety disorders such as panic disorder, generalized anxiety disorder, and social anxiety disorder. For PTSD specifically, small open-label studies suggest efficacy for PTSD, where its sleep-promoting properties may be particularly helpful.

The evidence base for mirtazapine in anxiety is smaller than for SSRIs. This is why SSRIs remain the first-line choice in most guidelines. Mirtazapine occupies a second-line or alternative role, appropriate when SSRIs have not worked or are poorly tolerated, or when the patient’s clinical profile specifically benefits from mirtazapine’s properties.

Who Benefits Most from Mirtazapine for Anxiety

The clinical profile of mirtazapine maps best onto specific patient presentations:

Anxiety with co-occurring depression. Mirtazapine addresses both through its dual mechanism. For patients who need treatment for anxiety and depression simultaneously, the single-agent approach simplifies treatment.

Anxiety with significant insomnia. The H1 blockade produces reliable sedation that improves sleep. For patients whose anxiety manifests significantly through disrupted sleep, mirtazapine’s sleep-promoting effects are a direct clinical benefit.

Anxiety with weight loss or appetite suppression. Depression and anxiety frequently reduce appetite and drive weight loss. Mirtazapine’s appetite-stimulating effect is therapeutically useful for this subset of patients.

Patients who have stopped SSRIs due to sexual side effects. Because mirtazapine does not cause sexual dysfunction, it is a meaningful alternative for patients whose adherence to prior treatments was undermined by this side effect.

Patients who have not responded to SSRIs. Mirtazapine’s mechanism is different enough from SSRI reuptake inhibition that some patients who did not respond to SSRIs respond to it.

Older patients with anxiety, insomnia, and low appetite. Mirtazapine is commonly used in the elderly population, where insomnia and low weight may benefit from its sedating and weight-gaining properties.

The Dose Conversation

The typical starting dose for mirtazapine is 15 mg once daily at bedtime. The dose may be increased in increments to a maximum of 45 mg per day.

Because mirtazapine is taken at bedtime, the sedation that is often a side effect in other antidepressants becomes a timing-matched feature. Patients who struggle with sleep disruption from anxiety take the medication when sleep disruption is the immediate problem.

Two things are worth knowing:

Lower doses are more sedating, not less. If sedation at 15 mg becomes problematic, increasing the dose may actually reduce it.

The anxiolytic and antidepressant effects typically take 4 to 6 weeks to fully develop, even if sedation is noticeable from the first dose. Patients who measure progress only by how they feel in the morning may discontinue before the medication has had time to work.

Side Effects to Know

Weight gain and increased appetite are the most consistently reported side effects. For patients who are underweight due to anxiety-related appetite suppression, this is a benefit. For others, it is a consideration to discuss before starting.

Sedation is common, particularly at lower doses and in the first few weeks. It typically diminishes over time and is manageable by taking the medication at bedtime.

No sexual dysfunction. Antidepressant-induced sexual dysfunction is estimated to occur in 18% of mirtazapine patients, lower than other antidepressants. For patients who left previous treatment because of this side effect, that difference directly affects adherence.

Restless legs syndrome has been reported in a subset of patients.

Discontinuation syndrome. Stopping mirtazapine abruptly can produce withdrawal symptoms. Tapering is recommended.

Black box warning. Like all antidepressants, mirtazapine carries the FDA black box warning for increased suicidal thoughts and behaviors in patients under 24. Monitoring in the early weeks of treatment is recommended.

About SiggyMD

Mirtazapine is within the scope of what SiggyMD prescribers can recommend when it is the right clinical fit for a patient’s presentation.

The daily check-in structure at SiggyMD is particularly useful with mirtazapine because the sedation and appetite effects can vary significantly across patients and doses. Tracking how sleep, appetite, and anxiety are responding over the first weeks gives a prescriber the data to optimize the dose rather than waiting for a quarterly appointment.

“Mirtazapine is one of the tools I reach for when the SSRI side effect profile has been a barrier, or when a patient’s anxiety is compounded by insomnia and poor appetite,” says Daniel Montville, MD, Psychiatrist at SiggyMD. “Its mechanism is genuinely different. The absence of sexual side effects is meaningful for long-term adherence. The question is always whether the sedation and weight gain are acceptable tradeoffs for that individual patient. That is a conversation worth having before assuming SSRIs are the only option.”

The anonymous intake at SiggyMD requires no name, email, or account to begin. A licensed prescriber reviews every treatment plan.

For more on anxiety medication options, see our comparison of anti-anxiety medications and their side effect profiles and our post on how long anxiety medications take to work.

Start your anonymous intake with SiggyMD to connect with a licensed prescriber who can evaluate whether mirtazapine or another treatment is the right fit for your clinical picture.

What Members Are Saying

LB

L.B., 34

Generalized Anxiety with Insomnia

“I had tried two SSRIs for anxiety and both caused sexual side effects that made me stop taking them. My prescriber at SiggyMD suggested mirtazapine. I sleep through the night now, which I had not done in years. The anxiety did not go away immediately but over six weeks it gradually improved. The weight gain is real but manageable.”

RP

R.P., 52

Anxiety and Depression with Weight Loss

“I had lost 12 pounds from anxiety and depression and was not eating. My prescriber recommended mirtazapine specifically because of the appetite effect. Within two weeks I was eating normally again. The depression and anxiety improved over a month.”

Member stories reflect real experiences. Names and identifying details have been changed to protect privacy. Results vary. You can begin anonymous intake without an account, name, email, or payment.

Sources

1. Landy K, Rosani A, Estevez R. Mirtazapine. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2024.

2. Caiazza C, et al. Clinical Potential of Mirtazapine in Anxiety and Trauma-Related Disorders: A Systematic Review and Meta-Analysis of Current Evidence. Human Psychopharmacology: Clinical and Experimental. 2026.

3. ScienceDirect. Mirtazapine overview. Accessed June 2026.

4. PsychDB. Mirtazapine (Remeron). Accessed June 2026.

5. Psychopharmacology Institute. Mirtazapine Essentials: MOA, Indications, Adverse Effects. Accessed June 2026.

6. Stimmel GL, Dopheide JA, Stahl SM. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy. 1997;17(1):10-21.

7. Wikipedia. Mirtazapine. Accessed June 2026.